Some thoughts on the reporting of adverse events in phase II cancer clinical trials.
Anderson
Stewart J
SJ
D016907:Adverse Drug Reaction Reporting Systems / Q000592:standards; D000970:Antineoplastic Agents / Q000009:adverse effects*; D017322:Clinical Trials, Phase II as Topic / Q000191:economics; D016208:Databases, Factual; D006801:Humans; D009316:National Institutes of Health (U.S.); D009369:Neoplasms / Q000188:drug therapy*; D011358:Product Surveillance, Postmarketing; D017594:Publication Bias; D012107:Research Design; D014481:United States
D000970:Antineoplastic Agents